Is It Too Late To Consider Albemarle (ALB) After A 144% One-Year Surge?

• Wondering if Albemarle at a last close of US$181.39 still offers value, or if the best gains are already in the rearview mirror.
• The stock has returned 9.4% over the last 7 days, 2.2% over 30 days, 26.0% year to date, and 143.8% over the past year, while the 3 year and 5 year returns sit at negative 15.5% and 31.7% respectively.
• Those swings in performance set the scene for a closer look at what might be driving sentiment, from changing expectations around Albemarle's end markets to shifting risk appetite in materials stocks. While this article does not focus on specific headlines, it uses that backdrop to frame how the stock looks on various valuation lenses.
• Despite the strong recent share price performance, Albemarle currently records a value score of 0 out of 6. The sections ahead will compare what different valuation methods suggest about the stock today, and then finish with a broader way to think about value that goes beyond the usual ratios and models.

Albemarle scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Albemarle Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those projections back to a single value today, using a required rate of return to reflect risk and the time value of money.

For Albemarle, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in US$. The latest trailing twelve month free cash flow is about $152.2 million. Analysts provide explicit forecasts out to 2028, with projected free cash flow of $777.6 million in that year. Beyond those years, further projections, such as the ten year path that runs through 2035, are extrapolated by Simply Wall St rather than being direct analyst estimates.

Bringing all of those projected cash flows back to today gives an estimated intrinsic value of about $86.07 per share. Compared with the recent share price of US$181.39, the DCF output suggests Albemarle is very expensive on this model, with an implied overvaluation of about 110.8%.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Albemarle may be overvalued by 110.8%. Discover 55 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Albemarle.

Approach 2: Albemarle Price vs Sales

For companies where earnings can be volatile or negative, investors often lean on the Price to Sales, or P/S, ratio because revenue tends to be more stable than profits and still reflects the scale of the business.

What counts as a "normal" or "fair" P/S ratio usually reflects how quickly revenue is expected to grow and how risky the business is. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk can point to a lower one.

Albemarle currently trades on a P/S ratio of 4.16x. That sits above both the Chemicals industry average of 1.02x and the peer group average of 2.72x, which on a simple comparison suggests a richer valuation versus many listed peers.

Simply Wall St’s Fair Ratio metric goes a step further. It estimates what a reasonable P/S multiple might be for Albemarle given its earnings growth profile, industry, profit margins, market cap and risk characteristics, rather than relying only on broad sector comparisons.

On this basis, Albemarle’s Fair Ratio is 1.79x, which is well below the current 4.16x. That gap indicates the shares look expensive relative to what the Fair Ratio implies.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Albemarle Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple way for you to spell out your story for Albemarle and connect that story to specific assumptions for future revenue, earnings, margins and a fair value estimate.

A Narrative links three pieces together: what you think is happening in the business, how that translates into a financial forecast, and what share price those numbers would justify, so you can clearly see whether your view lines up with the current market price.

On Simply Wall St’s Community page, Narratives are available as an easy to use tool, used by millions of investors. You can pick or adjust assumptions rather than build a full model from scratch.

Once you have a Narrative, it helps you decide whether Albemarle looks interesting to buy, hold or sell by comparing your Fair Value to the current share price and seeing whether the gap is large enough to matter for you.

Narratives also update automatically when fresh information such as earnings or news is added, so your view stays current without you having to constantly rebuild your work.

For Albemarle, one investor might align with the more bearish Narrative that ties to a Fair Value around US$58, while another might lean toward the more optimistic view closer to US$200. Seeing those side by side makes it clearer which story you find more reasonable.

For Albemarle, however, we will make it really easy for you with previews of two leading Albemarle Narratives:

🐂 Albemarle Bull Case

Fair Value: US$230.00

Implied discount to this Fair Value versus the last close of US$181.39: 21.2%.

Revenue growth used in this Narrative: 15.6%.

• Focuses on tighter lithium supply, growing electrification and Albemarle's cost improvements as supports for margins and earnings that are stronger than many forecasts assume.
• Builds in revenue of US$7.2b and earnings of US$1.6b by 2028, with a future P/E of 13.8x and a discount rate of about 8.2% to arrive at a bullish price target.
• Highlights risks such as prolonged weak lithium prices, political and regulatory pressure in key producing regions, potential underinvestment and new battery technologies that could reduce lithium demand.

🐻 Albemarle Bear Case

Fair Value: US$172.62

Implied premium to this Fair Value versus the last close of US$181.39: 5.1%.

Revenue growth used in this Narrative: 7.9%.

• Assumes Albemarle grows but at a more moderate pace, with earnings reaching about US$1.1b by 2028 and a future P/E of 11.9x, using a discount rate of roughly 8.0% to support a consensus target around US$85.47.
• Emphasizes lithium oversupply risk, ongoing price volatility and the chance that cost cuts and lower capital spending could limit long term volume growth and competitiveness.
• Flags uncertainties around EV demand, recycling, alternative chemistries and geopolitical or environmental constraints that could weigh on cash flows and margins over time.

Taken together, these Narratives present a range of views on Albemarle's value, so you can consider which set of assumptions is closer to your own expectations and whether the current price around US$181.39 aligns with that perspective.

Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com